ATAI Life Sciences
A biotechnology company pioneering mental health innovation.
Enterprise value
$390m
Share price
$2.19 ATAI
Company register number
HRB 239201 (München)
Recent deals
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | - | |
| Total Funding | 000k | ||
Mike Novogratz(exited)
Thor Bjorgolfsson(exited)
Subversive Capital(exited)
Apeiron Investment Group(exited)
Peter Thiel(exited)
Efrem Kamen(exited)
Christian Angermayer(exited)
Thiel Capital(exited)
Catalio Capital Management(exited)
Future Ventures(exited)
Alpha Wave Global(exited)
Pura Vida Investments(exited)
Woodline Partners(exited)
Fearless Ventures(exited)
Highline Capital Management(exited)
QC Ventures(exited)
Neo Kuma Ventures(exited)
Gaingels(exited)
Hercules Capital(exited)
FJ Labs(exited)
What If Ventures(exited)
Chris Heyer(exited)
Rafael Tamames(exited)
Marc Penkala(exited)
Patrick Schneider-Sikorsky(exited)
Sean Trigony(exited)
Marc penkala(exited)
Erman Turan(exited)
Steven Bartlett(exited)
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (99 %) | 35 % | (2 %) | 338 % | (84 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (515 %) | (61834 %) | (38551 %) | (32922 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (824 %) | (65401 %) | (12810 %) | (48464 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 235 % | 31894 % | 19810 % | 18005 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by ATAI Life Sciences
Edit
exited
ACQUISITION by ATAI Life Sciences Apr 2021
ACQUISITION by ATAI Life Sciences Jan 2021